TY - JOUR
T1 - Risk factors for symptomatic atrial fibrillation-analysis of an outpatient database
AU - Volgman, Annabelle Santos
AU - Dunn, Patrick
AU - Sundberg, Allison
AU - Conard, Scott
AU - Chakravarty, Pavitra
AU - Htway, Zin
AU - Waldo, Albert
AU - Albert, Christine
AU - Turakhia, Mintu P.
AU - Naccarelli, Gerald V.
N1 - Funding Information:
Dr. Waldo has received consulting fees/honoraria from Biosense Webster, AtriCure, Milestone Pharmaceuticals, Cardiac Insight, Correvio Pharms, Pfizer, Bristol-Myers Squibb; Dr. Naccarelli has received consulting fees/honoraria from Acesion, Glaxo-Smith-Kline, Janssen, Milestone, Omecos, and Sanofi; Dr. Albert has received funding from the NIH (R01 HL116690; Dr. Turkhia has received grants from Janssen, AstraZeneca, Veterans Health Administration, Boehringer Ingelheim, Cardiva Medical, Bristol Myers-Squibb, and the American Heart Association, and consulting fees/honoraria from Medtronic, AliveCor, Abbott, Precision Health Economics, Zipline Medical, IBeat, and iRrythm. The remaining authors have no disclosures.
Publisher Copyright:
© 2019 CardioFront LLC. All rights reserved.
PY - 2019
Y1 - 2019
N2 - Atrial fibrillation (AF) is the most common sustained arrhythmia encountered in practice and is the leading cause of debilitating strokes with significant economic burden. It is currently not known whether asymptomatic undiagnosed AF should be treated if detected by various screening methods. Currently United States guidelines have no recommendations to identify patients with asymptomatic undiagnosed AF due to lack of evidence. The American Heart Association Center for Health Technology & Innovation undertook a plan to identify tools in 3 phases that may be useful in improving outcomes in patients with undiagnosed AF. In phase I we sought to identify AF risk factors that can be used to develop a risk score to identify high-risk patients using a large commercial insurance dataset. The principal findings of this study show that individuals at high risk for AF are those of advance age, the presence of heart failure, coronary artery disease, hypertension, metabolic disorders, and hyperlipidemia. Our analysis also found that chronic respiratory failure was a significant risk factor for those over 65 years of age and chronic kidney disease for those less than 65 years of age.
AB - Atrial fibrillation (AF) is the most common sustained arrhythmia encountered in practice and is the leading cause of debilitating strokes with significant economic burden. It is currently not known whether asymptomatic undiagnosed AF should be treated if detected by various screening methods. Currently United States guidelines have no recommendations to identify patients with asymptomatic undiagnosed AF due to lack of evidence. The American Heart Association Center for Health Technology & Innovation undertook a plan to identify tools in 3 phases that may be useful in improving outcomes in patients with undiagnosed AF. In phase I we sought to identify AF risk factors that can be used to develop a risk score to identify high-risk patients using a large commercial insurance dataset. The principal findings of this study show that individuals at high risk for AF are those of advance age, the presence of heart failure, coronary artery disease, hypertension, metabolic disorders, and hyperlipidemia. Our analysis also found that chronic respiratory failure was a significant risk factor for those over 65 years of age and chronic kidney disease for those less than 65 years of age.
UR - http://www.scopus.com/inward/record.url?scp=85073739819&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073739819&partnerID=8YFLogxK
U2 - 10.4022/jafib.2141
DO - 10.4022/jafib.2141
M3 - Article
C2 - 31687065
AN - SCOPUS:85073739819
SN - 1941-6911
VL - 12
JO - Journal of Atrial Fibrillation
JF - Journal of Atrial Fibrillation
IS - 1
ER -